Curevac to present first cvgbm glioblastoma cancer vaccine clinical data at esmo 2024 congress

TÜbingen, germany and boston, ma / accesswire / september 9, 2024 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that the first clinical data from curevac's ongoing phase 1 cvgbm cancer vaccine study in patients with resected glioblastoma will be presented at the european society for medical oncology (esmo) congress (barcelona, spain, september 13-17, 2024).
CVAC Ratings Summary
CVAC Quant Ranking